Home › Islet Cell Adenoma
Islet Cell Adenoma clinical trials recruiting in the U.S.
12 studies for Islet Cell Adenoma are recruiting participants at sites across the United States.
Cities with the most studies
- St. Louis, MO5 studies
- Rochester, MN5 studies
- Los Angeles, CA5 studies
- Salt Lake City, UT4 studies
- Columbus, OH4 studies
- Lexington, KY4 studies
- Washington, DC4 studies
- Phoenix, AZ4 studies
- Portland, OR4 studies
- Chicago, IL4 studies
- Omaha, NE3 studies
- New York City, NY3 studies
- Seattle, WA3 studies
- Tampa, FL3 studies
- Jacksonville, FL3 studies
- Boston, MA3 studies
- Nashville, TN3 studies
- Philadelphia, PA3 studies
- Baltimore, MD3 studies
- Irvine, CA3 studies
- Cedar Rapids, IA3 studies
By state
- Arizona4 studies
- California7 studies
- Florida5 studies
- Illinois5 studies
- Iowa4 studies
- Kentucky4 studies
- Maryland4 studies
- Massachusetts3 studies
- Michigan3 studies
- Minnesota5 studies
- Missouri5 studies
- Nebraska3 studies
- New York4 studies
- Ohio5 studies
- Oregon4 studies
- Pennsylvania4 studies
- Tennessee4 studies
- Texas3 studies
- Utah4 studies
- Virginia3 studies
- Washington3 studies
Recently updated studies
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06943755A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06881992Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07165132Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05687123Nutrition Intervention for Pancreatic Cancer
Recruiting
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT07554560Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT05477576Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 17, 2026 · NCT04119024Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 9, 2026 · NCT00830557Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 26, 2026 · NCT05746182Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 9, 2026 · NCT06663072Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT05040360From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.